Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer

Axelsson, Rimma; Herlin, Gunnar; Bååth, Margaretha; Aspelin, Peter; Kölbeck, Karl‐Gustav

doi:10.1080/02841850701793777

Cited by 12 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Still, this is somewhat lower than both the sensitivity for detecting lung cancers [2, 6–11] with the same tracer and that for detecting lung cancer with 18 F-FDG-PET [6–8]. While 18 F-FDG uptake reflects a metabolic activity of the lesion and is not specific to tumors [6–8], overexpression of somatostatin receptors on tumor cells could give another valuable piece of information regarding tumor properties.…”

Section: Discussionmentioning

confidence: 99%

“…We used the same starting point for the imaging session as for the standard procedure in the detection of lung cancer, that is, 2 hours after injection [8, 10, 11]. During the last decade there has been a trend of performing a double-phase registration in order to increase specificity.…”

Section: Discussionmentioning

confidence: 99%

“…This tracer is 99m Tc-labeled, and demonstrates good imaging characteristics with a short investigation protocol. 99m Tc-depreotide has proven valuable in diagnosing pulmonary nodules [9–11]. We have previously used scintigraphy with 99m Tc-depreotide for the diagnosis of lung cancer, and showed an accurate discrimination between benign and malignant lesions with conventional gamma cameras [6, 9, 11].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue

Herlin

Ideström

Lundell

et al. 2011

International Journal of Molecular Imaging

View full text Add to dashboard Cite

Background. While the surface of a cell normally has some amount of somatostatin receptors, these receptors are overexpressed to a very high degree in multiple neoplastic diseases. No data exist for esophageal carcinoma. Purpose. To find out whether esophageal carcinoma could be imaged using somatostatin receptor scintigraphy. Material and Methods. 34 patients with esophageal lesions were prospectively examined by 99mTc-depreotide scintigraphy 2 and 4 hours after injection. Quantitative evaluation of 99mTc-depreotide uptake was performed around the lesion (T) and in healthy lung parenchyma (B). The relative uptake was calculated as T−B/B. Scintigraphy results were compared with histopathology from surgery or biopsy specimens from endoscopic ultrasonography. Results. 21 patients had esophageal cancer, and 13 lesions were benign. Visual assessment revealed positive 99mTc-depreotide uptake in 16 of the 21 cancers. The 13 patients without cancer had no depreotide uptake. The Mann-Whitney U test showed a statistically significant difference (P < .005) between 99mTc-depreotide uptake in malignant and benign lesions, for both the 2-hour and the 4-hour measurements. Conclusion. Scintigraphic examination with 99mTc-depreotide is feasible for imaging esophageal cancer, but the method is not suitable neither for screening or primary diagnosis, because of methods modest sensitivity. Our first results showed high specificity which should be used with caution, as the number of patients was relatively low. Further studies are needed to determine the role of the method.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue

Herlin

Ideström

Lundell

et al. 2011

International Journal of Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…The 99m Tc-labeled agent, 99m Tc-Depreotide, has received regulatory approval in the United States and Europe for use in the detection of lung cancer [ 50 ]. It binds to a wide range of SSTR subtypes (SSTR2, SSTR3, and SSTR5) and has shown promise in diagnosing a variety of tumor types [ 51 – 53 ], including some OctreoScan negative NETs [ 10 ]. 111 In-DOTA-lanreotide is another γ -emitting tracer with different affinity for SSTR subtypes compared to [ 111 In-DTPA 0 ]octreotide.…”

Section: Somatostatin Receptor Based Imagingmentioning

confidence: 99%

Somatostatin Receptor Based Imaging and Radionuclide Therapy

Zhang

2015

BioMed Research International

View full text Add to dashboard Cite

Somatostatin (SST) receptors (SSTRs) belong to the typical 7-transmembrane domain family of G-protein-coupled receptors. Five distinct subtypes (termed SSTR1-5) have been identified, with SSTR2 showing the highest affinity for natural SST and synthetic SST analogs. Most neuroendocrine tumors (NETs) have high expression levels of SSTRs, which opens the possibility for tumor imaging and therapy with radiolabeled SST analogs. A number of tracers have been developed for the diagnosis, staging, and treatment of NETs with impressive results, which facilitates the applications of human SSTR subtype 2 (hSSTr2) reporter gene based imaging and therapy in SSTR negative or weakly positive tumors to provide a novel approach for the management of tumors. The hSSTr2 gene can act as not only a reporter gene for in vivo imaging, but also a therapeutic gene for local radionuclide therapy. Even a second therapeutic gene can be transfected into the same tumor cells together with hSSTr2 reporter gene to obtain a synergistic therapeutic effect. However, additional preclinical and especially translational and clinical researches are needed to confirm the value of hSSTr2 reporter gene based imaging and therapy in tumors.

show abstract

“…99m Tc-depreotide scintigraphy has been shown to be a potentially valuable tool in the diagnosis of solitary pulmonary nodules and lymph node metastases [2, 7–10]. Our initial experience has also revealed that scintigraphic examination with 99m Tc-depreotide is feasible for imaging of oesophageal cancer [11].…”

Section: Introductionmentioning

confidence: 99%

Quantitative Assessment of^99mTc-Depreotide Uptake in Oesophageal Cancer and Precursor Conditions and Its Reflection in Immunohistochemically Detected Somatostatin Receptors

Herlin

Lundell

Öst

et al. 2012

Radiology Research and Practice

View full text Add to dashboard Cite

Background. Somatostatin receptors (SSTRs) are over-expressed in several tumors making it possible for imaging with labelled SSTR. A previous study showed feasibility to image oesophageal cancer with SSTR analogue 99mTc-depreotide. Purpose. (1) To investigate expression of the SSTRs in different types of esophageal carcinoma and (2) to correlate such an expression with 99mTc-depreotide uptake in these lesions. Material and Methods. Total 28 patients (17 with esophageal cancer and 11 with Barrett's esophagus) were examined with 99mTc-depreotide scintigraphy. The SSTR2A, SSTR2B, SSTR3, and SSTR5 were analyzed immunohistochemically in the lesion samples. Results. Among the patients with adenocarcinoma 10/11 expressed different amounts of SSTRs, while SSTRs were absent in 5/6 patients with Squamous cell carcinoma (Sqcc). There was no correlation neither between the 99mTc-depreotide uptake and the amount of SSTRs nor between the amount of SSTRs and differentiation grade of the tumor. Conclusions. (1) SSTRs are expressed in esophageal carcinoma and more abundantly so in adenocancer specimens; (2) in vivo 99mTc-depreotide uptake does not obviously correlate with the immunohistochemically detection of SSTRs of different subtypes in esophageal carcinoma.

show abstract

Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer

Abstract: 99mTc-depreotide scintigraphy has a high sensitivity in detecting lung cancer. The method is useful in decision-making with respect to surgery.

Cited by 12 publications

References 18 publications

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue

Somatostatin Receptor Based Imaging and Radionuclide Therapy

Quantitative Assessment of^99mTc-Depreotide Uptake in Oesophageal Cancer and Precursor Conditions and Its Reflection in Immunohistochemically Detected Somatostatin Receptors

Contact Info

Product

Resources

About

Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer

Abstract: 99mTc-depreotide scintigraphy has a high sensitivity in detecting lung cancer. The method is useful in decision-making with respect to surgery.

Cited by 12 publications

References 18 publications

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue

Somatostatin Receptor Based Imaging and Radionuclide Therapy

Quantitative Assessment of99mTc-Depreotide Uptake in Oesophageal Cancer and Precursor Conditions and Its Reflection in Immunohistochemically Detected Somatostatin Receptors

Contact Info

Product

Resources

About

Quantitative Assessment of^99mTc-Depreotide Uptake in Oesophageal Cancer and Precursor Conditions and Its Reflection in Immunohistochemically Detected Somatostatin Receptors